Animal clinical trials conducted by Li, S et al. in 2015 demonstrated (Li, S et al, 2015) that DEX decreases the secretion of cytokines (TNF-α, IL-6) following endotoxin injection, and dexmedetomidine reduces endotoxemia in a dose-dependent manner in a rat model of induced shock. The gene discussed is TNF; the disease is serum lipopolysaccharide activity.